Target validation in drug discovery:
Gespeichert in:
| Format: | Elektronisch E-Book |
|---|---|
| Sprache: | English |
| Veröffentlicht: |
Amsterdam
Academic Press
c2007
|
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Beschreibung: | This work presents a comprehensive contemporary framework for approaching target validation in drug discovery. It begins with a detailed description of new enabling technologies, including aptamers, RNA interference, functional genomics, and proteomics. The next section looks at biologic drug development with in-depth discussion of lessons learned from such well-known cases as Erbitux, Herceptin, and Avastin. Additional targets known as "second generation" drugs, which can be identified when disease pathways are validated by biologics, present new possible small molecule therapeutics and serve as the focus of the final section of the book Includes bibliographical references and index |
| Beschreibung: | 1 Online-Ressource (xii, 279 p.) |
| ISBN: | 9780123693938 0123693934 9780080465975 0080465978 |
Internformat
MARC
| LEADER | 00000nmm a2200000zc 4500 | ||
|---|---|---|---|
| 001 | BV042312168 | ||
| 003 | DE-604 | ||
| 005 | 00000000000000.0 | ||
| 007 | cr|uuu---uuuuu | ||
| 008 | 150129s2007 |||| o||u| ||||||eng d | ||
| 020 | |a 9780123693938 |9 978-0-12-369393-8 | ||
| 020 | |a 0123693934 |9 0-12-369393-4 | ||
| 020 | |a 9780080465975 |c electronic bk. |9 978-0-08-046597-5 | ||
| 020 | |a 0080465978 |c electronic bk. |9 0-08-046597-8 | ||
| 035 | |a (ZDB-33-EBS)ocn162130366 | ||
| 035 | |a (OCoLC)162130366 | ||
| 035 | |a (DE-599)BVBBV042312168 | ||
| 040 | |a DE-604 |b ger |e aacr | ||
| 041 | 0 | |a eng | |
| 049 | |a DE-1046 | ||
| 082 | 0 | |a 615/.19 |2 22 | |
| 245 | 1 | 0 | |a Target validation in drug discovery |c editors, Brian W. Metcalf and Susan Dillon |
| 264 | 1 | |a Amsterdam |b Academic Press |c c2007 | |
| 300 | |a 1 Online-Ressource (xii, 279 p.) | ||
| 336 | |b txt |2 rdacontent | ||
| 337 | |b c |2 rdamedia | ||
| 338 | |b cr |2 rdacarrier | ||
| 500 | |a This work presents a comprehensive contemporary framework for approaching target validation in drug discovery. It begins with a detailed description of new enabling technologies, including aptamers, RNA interference, functional genomics, and proteomics. The next section looks at biologic drug development with in-depth discussion of lessons learned from such well-known cases as Erbitux, Herceptin, and Avastin. Additional targets known as "second generation" drugs, which can be identified when disease pathways are validated by biologics, present new possible small molecule therapeutics and serve as the focus of the final section of the book | ||
| 500 | |a Includes bibliographical references and index | ||
| 650 | 4 | |a Médicaments / Développement | |
| 650 | 4 | |a Médicaments / Essais cliniques | |
| 650 | 4 | |a Criblage à haut débit (Développement des médicaments) | |
| 650 | 7 | |a MEDICAL / Drug Guides |2 bisacsh | |
| 650 | 7 | |a MEDICAL / Pharmacology |2 bisacsh | |
| 650 | 7 | |a MEDICAL / Pharmacy |2 bisacsh | |
| 650 | 7 | |a MEDICAL / Nursing / Pharmacology |2 bisacsh | |
| 650 | 7 | |a Médicaments / Mise au point |2 ram | |
| 650 | 7 | |a Médicaments / Essais cliniques |2 ram | |
| 650 | 7 | |a Criblage pharmacologique |2 ram | |
| 650 | 7 | |a Drug development |2 fast | |
| 650 | 7 | |a Drugs / Testing |2 fast | |
| 650 | 7 | |a High throughput screening (Drug development) |2 fast | |
| 650 | 4 | |a Drug Design | |
| 650 | 4 | |a Drug Delivery Systems | |
| 650 | 4 | |a Technology, Pharmaceutical | |
| 650 | 4 | |a Medizin | |
| 650 | 4 | |a Drug development | |
| 650 | 4 | |a Drugs |x Testing | |
| 650 | 4 | |a High throughput screening (Drug development) | |
| 700 | 1 | |a Metcalf, Brian W. |e Sonstige |4 oth | |
| 700 | 1 | |a Dillon, Susan |e Sonstige |4 oth | |
| 856 | 4 | 0 | |u http://www.sciencedirect.com/science/book/9780123693938 |x Verlag |3 Volltext |
| 912 | |a ZDB-33-ESD |a ZDB-33-EBS | ||
| 940 | 1 | |q FAW_PDA_ESD | |
| 940 | 1 | |q FLA_PDA_ESD | |
| 999 | |a oai:aleph.bib-bvb.de:BVB01-027749159 | ||
Datensatz im Suchindex
| _version_ | 1804152902589087744 |
|---|---|
| any_adam_object | |
| building | Verbundindex |
| bvnumber | BV042312168 |
| collection | ZDB-33-ESD ZDB-33-EBS |
| ctrlnum | (ZDB-33-EBS)ocn162130366 (OCoLC)162130366 (DE-599)BVBBV042312168 |
| dewey-full | 615/.19 |
| dewey-hundreds | 600 - Technology (Applied sciences) |
| dewey-ones | 615 - Pharmacology and therapeutics |
| dewey-raw | 615/.19 |
| dewey-search | 615/.19 |
| dewey-sort | 3615 219 |
| dewey-tens | 610 - Medicine and health |
| discipline | Medizin |
| format | Electronic eBook |
| fullrecord | <?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>02869nmm a2200637zc 4500</leader><controlfield tag="001">BV042312168</controlfield><controlfield tag="003">DE-604</controlfield><controlfield tag="005">00000000000000.0</controlfield><controlfield tag="007">cr|uuu---uuuuu</controlfield><controlfield tag="008">150129s2007 |||| o||u| ||||||eng d</controlfield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">9780123693938</subfield><subfield code="9">978-0-12-369393-8</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">0123693934</subfield><subfield code="9">0-12-369393-4</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">9780080465975</subfield><subfield code="c">electronic bk.</subfield><subfield code="9">978-0-08-046597-5</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">0080465978</subfield><subfield code="c">electronic bk.</subfield><subfield code="9">0-08-046597-8</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ZDB-33-EBS)ocn162130366</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(OCoLC)162130366</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)BVBBV042312168</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-604</subfield><subfield code="b">ger</subfield><subfield code="e">aacr</subfield></datafield><datafield tag="041" ind1="0" ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="049" ind1=" " ind2=" "><subfield code="a">DE-1046</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">615/.19</subfield><subfield code="2">22</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Target validation in drug discovery</subfield><subfield code="c">editors, Brian W. Metcalf and Susan Dillon</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">Amsterdam</subfield><subfield code="b">Academic Press</subfield><subfield code="c">c2007</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">1 Online-Ressource (xii, 279 p.)</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="500" ind1=" " ind2=" "><subfield code="a">This work presents a comprehensive contemporary framework for approaching target validation in drug discovery. It begins with a detailed description of new enabling technologies, including aptamers, RNA interference, functional genomics, and proteomics. The next section looks at biologic drug development with in-depth discussion of lessons learned from such well-known cases as Erbitux, Herceptin, and Avastin. Additional targets known as "second generation" drugs, which can be identified when disease pathways are validated by biologics, present new possible small molecule therapeutics and serve as the focus of the final section of the book</subfield></datafield><datafield tag="500" ind1=" " ind2=" "><subfield code="a">Includes bibliographical references and index</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Médicaments / Développement</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Médicaments / Essais cliniques</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Criblage à haut débit (Développement des médicaments)</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">MEDICAL / Drug Guides</subfield><subfield code="2">bisacsh</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">MEDICAL / Pharmacology</subfield><subfield code="2">bisacsh</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">MEDICAL / Pharmacy</subfield><subfield code="2">bisacsh</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">MEDICAL / Nursing / Pharmacology</subfield><subfield code="2">bisacsh</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Médicaments / Mise au point</subfield><subfield code="2">ram</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Médicaments / Essais cliniques</subfield><subfield code="2">ram</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Criblage pharmacologique</subfield><subfield code="2">ram</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Drug development</subfield><subfield code="2">fast</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Drugs / Testing</subfield><subfield code="2">fast</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">High throughput screening (Drug development)</subfield><subfield code="2">fast</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Drug Design</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Drug Delivery Systems</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Technology, Pharmaceutical</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Medizin</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Drug development</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Drugs</subfield><subfield code="x">Testing</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">High throughput screening (Drug development)</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Metcalf, Brian W.</subfield><subfield code="e">Sonstige</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Dillon, Susan</subfield><subfield code="e">Sonstige</subfield><subfield code="4">oth</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">http://www.sciencedirect.com/science/book/9780123693938</subfield><subfield code="x">Verlag</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">ZDB-33-ESD</subfield><subfield code="a">ZDB-33-EBS</subfield></datafield><datafield tag="940" ind1="1" ind2=" "><subfield code="q">FAW_PDA_ESD</subfield></datafield><datafield tag="940" ind1="1" ind2=" "><subfield code="q">FLA_PDA_ESD</subfield></datafield><datafield tag="999" ind1=" " ind2=" "><subfield code="a">oai:aleph.bib-bvb.de:BVB01-027749159</subfield></datafield></record></collection> |
| id | DE-604.BV042312168 |
| illustrated | Not Illustrated |
| indexdate | 2024-07-10T01:18:06Z |
| institution | BVB |
| isbn | 9780123693938 0123693934 9780080465975 0080465978 |
| language | English |
| oai_aleph_id | oai:aleph.bib-bvb.de:BVB01-027749159 |
| oclc_num | 162130366 |
| open_access_boolean | |
| owner | DE-1046 |
| owner_facet | DE-1046 |
| physical | 1 Online-Ressource (xii, 279 p.) |
| psigel | ZDB-33-ESD ZDB-33-EBS FAW_PDA_ESD FLA_PDA_ESD |
| publishDate | 2007 |
| publishDateSearch | 2007 |
| publishDateSort | 2007 |
| publisher | Academic Press |
| record_format | marc |
| spelling | Target validation in drug discovery editors, Brian W. Metcalf and Susan Dillon Amsterdam Academic Press c2007 1 Online-Ressource (xii, 279 p.) txt rdacontent c rdamedia cr rdacarrier This work presents a comprehensive contemporary framework for approaching target validation in drug discovery. It begins with a detailed description of new enabling technologies, including aptamers, RNA interference, functional genomics, and proteomics. The next section looks at biologic drug development with in-depth discussion of lessons learned from such well-known cases as Erbitux, Herceptin, and Avastin. Additional targets known as "second generation" drugs, which can be identified when disease pathways are validated by biologics, present new possible small molecule therapeutics and serve as the focus of the final section of the book Includes bibliographical references and index Médicaments / Développement Médicaments / Essais cliniques Criblage à haut débit (Développement des médicaments) MEDICAL / Drug Guides bisacsh MEDICAL / Pharmacology bisacsh MEDICAL / Pharmacy bisacsh MEDICAL / Nursing / Pharmacology bisacsh Médicaments / Mise au point ram Médicaments / Essais cliniques ram Criblage pharmacologique ram Drug development fast Drugs / Testing fast High throughput screening (Drug development) fast Drug Design Drug Delivery Systems Technology, Pharmaceutical Medizin Drug development Drugs Testing High throughput screening (Drug development) Metcalf, Brian W. Sonstige oth Dillon, Susan Sonstige oth http://www.sciencedirect.com/science/book/9780123693938 Verlag Volltext |
| spellingShingle | Target validation in drug discovery Médicaments / Développement Médicaments / Essais cliniques Criblage à haut débit (Développement des médicaments) MEDICAL / Drug Guides bisacsh MEDICAL / Pharmacology bisacsh MEDICAL / Pharmacy bisacsh MEDICAL / Nursing / Pharmacology bisacsh Médicaments / Mise au point ram Médicaments / Essais cliniques ram Criblage pharmacologique ram Drug development fast Drugs / Testing fast High throughput screening (Drug development) fast Drug Design Drug Delivery Systems Technology, Pharmaceutical Medizin Drug development Drugs Testing High throughput screening (Drug development) |
| title | Target validation in drug discovery |
| title_auth | Target validation in drug discovery |
| title_exact_search | Target validation in drug discovery |
| title_full | Target validation in drug discovery editors, Brian W. Metcalf and Susan Dillon |
| title_fullStr | Target validation in drug discovery editors, Brian W. Metcalf and Susan Dillon |
| title_full_unstemmed | Target validation in drug discovery editors, Brian W. Metcalf and Susan Dillon |
| title_short | Target validation in drug discovery |
| title_sort | target validation in drug discovery |
| topic | Médicaments / Développement Médicaments / Essais cliniques Criblage à haut débit (Développement des médicaments) MEDICAL / Drug Guides bisacsh MEDICAL / Pharmacology bisacsh MEDICAL / Pharmacy bisacsh MEDICAL / Nursing / Pharmacology bisacsh Médicaments / Mise au point ram Médicaments / Essais cliniques ram Criblage pharmacologique ram Drug development fast Drugs / Testing fast High throughput screening (Drug development) fast Drug Design Drug Delivery Systems Technology, Pharmaceutical Medizin Drug development Drugs Testing High throughput screening (Drug development) |
| topic_facet | Médicaments / Développement Médicaments / Essais cliniques Criblage à haut débit (Développement des médicaments) MEDICAL / Drug Guides MEDICAL / Pharmacology MEDICAL / Pharmacy MEDICAL / Nursing / Pharmacology Médicaments / Mise au point Criblage pharmacologique Drug development Drugs / Testing High throughput screening (Drug development) Drug Design Drug Delivery Systems Technology, Pharmaceutical Medizin Drugs Testing |
| url | http://www.sciencedirect.com/science/book/9780123693938 |
| work_keys_str_mv | AT metcalfbrianw targetvalidationindrugdiscovery AT dillonsusan targetvalidationindrugdiscovery |